Deal Spree Continues as Celgene Nabs Juno in $9B Deal
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace
Hepatares Co-Founder to Helm Merck's New R&D Center in the UK
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace
Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ
The deal has Sanofi paying $105 per share in cash. Source: BioSpace
Bay Area's Eureka Therapeutics Banks $60M
Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors. Source: BioSpace
What You Need to Know About Indalo Therapeutics
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. Source: BioSpace
Up-and-Coming Chinese Biotech BeiGene Gets $750M Worth of Love From U.S. Investors
The company will use the cash for working capital and general corporate purposes, including R&D activities. Source: BioSpace
New York's Tyme Jumps as Pancreatic Cancer Drug Shines in Early-Stage Study
The data was presented at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, Calif. today. Source: BioSpace
Why This Seattle Biotech Could be an M&A Target
Immune Design is a clinical-stage immunotherapy company. Source: BioSpace
Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei
Dr. Marshall will leave Sosei at the end of February 2018. Source: BioSpace
What You Need to Know About Jecure Therapeutics
Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis. Source: BioSpace
- Go to the previous page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- …
- 288
- Go to the next page